IP Library Granted Patent US 7,659,118
Granted Patent B2
US 7,659,118 · App. 11/238,234 · Granted Feb 9, 2010

Multipotent adult stem cells

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,659,118
App. No.
11/238,234
Granted
Feb 9, 2010
Kind
B2
Abstract

The invention provides isolated stem cells of non-embryonic origin that can be maintained in culture in the undifferentiated state or differentiated to form cells of multiple tissue types. Also provided are methods of isolation and culture, as well as therapeutic uses for the isolated cells.

Claims (12)

1. A cell culture comprising isolated expanded human multipotent, non-embryonic, non-germ cells that can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages and express telomerase, said cells having undergone at least 10-40 cell doublings in culture.

2. A cell culture comprising isolated expanded human multipotent, non-embryonic, non-germ, cells that can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages, express telomerase, and have been obtained by culture of non-embryonic, non-germ tissue, the telomerase-expressing cells having undergone at least 10-40 cell doublings in culture.

3. The cell culture of claim 1 or 2 wherein the telomerase-expressing cells have undergone 10 cell doublings.

4. The cell culture of claim 1 or 2 wherein the telomerase-expressing cells have undergone 20 cell doublings.

5. The cell culture of claim 1 or 2 wherein the telomerase-expressing cells have undergone 30 cell doublings.

6. The cell culture of claim 1 or 2 wherein the telomerase-expressing cells have undergone 40 cell doublings.

7. The cell culture of claim 1 or 2 , wherein the cells are genetically modified.

8. The cell culture of claim 7 wherein the modification comprises introducing a selectable or screenable marker gene into the cells.

9. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and isolated expanded human multipotent, non-embryonic, non-germ cells that can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages and express telomerase, said cells having undergone at least 10-40 cell doublings in culture, said cells obtained from the cell culture of claim 1 or 2 .

10. A method for making a pharmaceutical composition comprising admixing a pharmaceutically acceptable carrier and isolated expanded human multipotent, non-embryonic, non-germ cells that can differentiate into at least one cell type of each of the endodermal, ectodermal, and mesodermal embryonic lineages and express telomerase, said cells having undergone at least 10-40 cell doublings in culture, said cells obtained from the cell culture of claim 1 or 2 .

11. A method for making the cell culture of claim 1 or 2 , said method comprising introducing the telomerase-expressing cells into cell culture medium and expanding said cells such that said cells undergo at least 10-40 cell doublings in culture.

12. The cell culture of claim 1 or 2 wherein the telomerase-expressing cells have undergone greater than 40 cell doublings.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2008
From: REGENESYS, LLC
To: ATHERSYS, INC.
Reel/Frame 020510/0045 →
CHANGE OF NAME Recorded Feb 14, 2008
From: ATHERSYS, INC.
To: ABT HOLDING COMPANY
Reel/Frame 020519/0448 →
MERGER Recorded Feb 13, 2008
From: MCL LLC
To: REGENESYS, LLC
Reel/Frame 020502/0588 →